Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI - ...

Scientists are investigating whether a concentrated hop extract can trigger the gut’s “bitter brake,” a natural signaling pathway that may help reduce hunger and support appetite control.

YCT-529 inhibits retinoic acid receptor alpha to suppress sperm production reversibly. Currently in Phase 1b/2a trials, the compound has shown promise in preclinical models and aims to expand ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 3:10 PM ESTCompany ParticipantsEric BrownGiacomo Salvadore - Chief ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...

A shot that keeps a mare from getting pregnant sounds simple. In practice, it is one of the messier problems in wildlife management, where every extra dose means another chase, another dart, another ...

CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are ...

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and ...

Eisai will present lecanemab data focused on real-world efficacy and safety, as well as four-year data from the Clarity AD Open-Label Extension trial. Eisai will also host one industry-sponsored ...